New hope for leukemia patients who run out of options
NCT ID NCT03182244
Summary
This study tested whether a new targeted pill (gilteritinib) works better than standard chemotherapy for adults with a specific type of acute myeloid leukemia (AML) that has returned or not responded to first treatment. The goal was to see if the new drug helps patients live longer and achieve remission. Researchers compared the two treatments in 276 participants to measure survival, remission rates, and safety.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AML WITH FLT3 MUTATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Site CN101
Tianjin, China
-
Site CN102
Guangzhou, China
-
Site CN103
Beijing, China
-
Site CN105
Wuhan, China
-
Site CN106
Qingdao, China
-
Site CN107
Hangzhou, China
-
Site CN108
Beijing, China
-
Site CN109
Beijing, China
-
Site CN110
Beijing, China
-
Site CN113
Zhengzhou, China
-
Site CN114
Guangzhou, China
-
Site CN116
Changchun, China
-
Site CN117
Jinan, China
-
Site CN118
Hefei, China
-
Site CN119
Fuzhou, China
-
Site CN120
Changsha, China
-
Site CN121
Guangzhou, China
-
Site CN122
Xi'an, China
-
Site CN123
Huangpu Qu, China
-
Site CN125
Shenyang, China
-
Site CN126
Shanghai, China
-
Site CN128
Nanjing, China
-
Site CN129
Shanghai, China
-
Site CN130
Guiyang, China
-
Site CN131
Beijing, China
-
Site CN132
Zhangzhou, China
-
Site CN133
Lanzhou, China
-
Site CN136
Zhengzhou, China
-
Site MY301
Johor Bahru, Malaysia
-
Site MY302
Kuala Lumpur, Malaysia
-
Site MY303
Pulau Pinang, Malaysia
-
Site MY304
Kota Kinabalu, Malaysia
-
Site MY305
George Town, Malaysia
-
Site MY306
Ampang, Malaysia
-
Site RU501
Saint Petersburg, Russia
-
Site RU502
Saint Petersburg, Russia
-
Site RU504
Krasnoyarsk, Russia
-
Site RU506
Kemerovo, Russia
-
Site RU507
Saint Petersburg, Russia
-
Site RU508
Moscow, Russia
-
Site RU509
Moscow, Russia
-
Site SG401
Singapore, Singapore
-
Site SG402
Singapore, Singapore
-
Site SG403
Singapore, Singapore
-
Site TH201
Khon Kaen, Thailand
-
Site TH202
Khon Kaen, Thailand
-
Site TH203
Bangkok, Thailand
-
Site TH204
Chiang Mai, Thailand
-
Site TH205
Bangkok, Thailand
Conditions
Explore the condition pages connected to this study.